SANA vs ZVRA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ZVRA Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zevra Therapeutics, Inc. Common Stock (ZVRA) driven by superior Valuation, Growth & Margin, Momentum & Technical while SANA counters with relative strength in Options & Structure. Fundamentally, SANA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ZVRA at 10.4x Forward P/E and 31.5% operating margin (+44.9% YoY). In options structure, SANA sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro) against ZVRA sits in BREAKDOWN (18th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SANA | ZVRA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $605.3M | $540.3M | Larger Scale | SANA |
| Trailing P/E Ratio Valuation | N/M | 7.4x | Lower Multiple | ZVRA |
| Forward P/E Ratio Valuation | N/M | 10.4x | Lower Multiple | ZVRA |
| Revenue Growth (YoY) Growth | +0.0% | +44.9% | Higher Growth | ZVRA |
| Operating Margin (TTM) Profitability | 0.0% | 31.5% | Higher Margin | ZVRA |
| Net Profit Margin Profitability | 0.0% | 52.8% | Higher Margin | ZVRA |
| Return on Equity (ROE) Capital Efficiency | -79.5% | 41.9% | Higher ROE | ZVRA |
| 52-Week Range Position Momentum | 1% ($2โ$5) | 18% ($8โ$15) | Stronger Trend | ZVRA |
| Beta / 30D Volatility Risk Regime | 1.82ฮฒ ยท 78% Vol | 1.19ฮฒ ยท 94% Vol | Lower Realized Risk | SANA |
| Unified Institutional Score Composite Signal | 44.3 / 100 (HOLD) | 49.4 / 100 (HOLD) | Higher Composite | ZVRA |